Martin Samuel Bates
- SEC CIK
- 0001709024
No open-market purchases or sales filed in the past year.
Current role at each company
- CLDX Celldex Therapeutics, Inc.SVP AND CFOas of Jun 29, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Martin Samuel Bates as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 18, 2024 (view filing) | Jun 14 | 4 days | Martin Samuel BatesSVP AND CFO | SSale | −17.2K | $35.42 | −$608.2K | −37.9%28.1K after | |
| Jun 3, 2024 (view filing) | May 30 | 4 days | Martin Samuel BatesSVP AND CFO | SSale | −35.0K | $34.05 | −$1.19M | −58.2%25.1K after | |
| Aug 15, 2022 (view filing) | Aug 11-12 | 4 days | Martin Samuel BatesSVP AND CFO | SSale | −20.0K | $36.52 | −$730.4K | −45.1%24.4K after | 4 lots |
| Dec 28, 2021 (view filing) | Dec 23 | 5 days | Martin Samuel BatesSVP and CFO | SSale | −9.50K | $42.00 | −$399.0K | −28.0%24.4K after | |
| Nov 17, 2021 (view filing) | Nov 15 | 2 days | Martin Samuel BatesSVP and CFO | SSale | −9.50K | $43.56 | −$413.9K | −26.1%26.9K after | 2 lots |
| Aug 12, 2021 (view filing) | Aug 10 | 2 days | Martin Samuel BatesSVP and CFO | SSale | −2.74K | $45.25 | −$123.9K | −8.5%29.4K after | 2 lots |